Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 24

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 24
---
 |

Executive Officers of the Combined Company Following the Merger (see page 31) Immediately following the Merger, the executive management team of the MIRA is expected to remain the same as prior to the Merger and be comprised of the following individuals with such additional officers as may be added by the combined company:

| Name         |     | Position          
 with MIRA         |
| Erez         
 Aminov       |     | Chief             
 Executive Officer |
| Alan         
 Weichselbaum |     | Chief             
 Financial Officer |

Directors of the Combined Company Following the Merger (see page 32) Following the Merger, MIRA is expected to maintain four of the directors that were in office prior to the Merger, comprised of Matthew Pratt Whalen, CPA; Erez Aminov, Edward MacPherson and Dr. Matthew Del Giudice, with Dr. Denil Nanji Shekhat being replaced by Kelly Stackpole, the current CEO of SKNY, at the closing of the Merger, each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. For more information about the executive officers and directors of MIRA following the Merger, please see the section titled “ Management Following the Merger.” Interests of the MIRA Directors, Executive Officers and Affiliate Shareholders in the Merger (see page 31) In considering the recommendation of the MIRA Board with respect to the issuance of MIRA Common Stock pursuant to the Merger Agreement and the other matters to be acted upon by MIRA’s stockholders at the MIRA Annual Meeting, MIRA’s stockholders should be aware that certain members of the MIRA Board and executive officers of MIRA have interests in the Merger that may be different from, or in addition to, interests of other MIRA stockholders. As of June 6, 2025, MIRA’s directors and executive officers (including affiliates) beneficially own in the aggregate approximately 21.00% of the outstanding shares of MIRA Common Stock. The conflicts of interests of MIRA’s officers and directors in connection with the Merger related are discussed in greater detail in the section titled “ The Merger—Interests of the MIRA Directors, Executive Officers and Affiliate Shareholders in the Merger” on page 31 of this proxy statement. Material U.S. Federal Income Tax Consequences of the Merger (see page 32) MIRA and SKNY intend the Merger to qualify as a reorganization